Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Liabilities (2016 - 2025)

ImmunityBio (IBRX) has disclosed Total Liabilities for 12 consecutive years, with $499.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 42.65% to $499.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $499.6 million, a 42.65% decrease, with the full-year FY2025 number at $499.6 million, down 42.65% from a year prior.
  • Total Liabilities was $499.6 million for Q4 2025 at ImmunityBio, down from $1.0 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $1.1 billion in Q2 2024 to a low of $337.6 million in Q1 2022.
  • A 5-year average of $797.8 million and a median of $857.1 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: soared 1516.03% in 2021, then plummeted 42.65% in 2025.
  • ImmunityBio's Total Liabilities stood at $712.8 million in 2021, then rose by 13.94% to $812.2 million in 2022, then soared by 34.26% to $1.1 billion in 2023, then dropped by 20.11% to $871.1 million in 2024, then tumbled by 42.65% to $499.6 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Total Liabilities are $499.6 million (Q4 2025), $1.0 billion (Q3 2025), and $971.9 million (Q2 2025).